TPThomas Pataillot-Meakin

Thomas Pataillot-Meakin

*This is an algorithmically generated author record based on publicly available information.

Thomas Pataillot-Meakin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells

    by Emma Halliwell, Alice Vitali, Henrike Muller, Maria Alonso-Ferrero, Marta Barisa, Artemis Gavriil, Alice Piapi, Clara Leboreiro-Babe, Talia Gileadi, Jenny Yeung, et al.


  • Open Access

    Detection of YAP1 and AR-V7 mRNA for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform

    by Joseph Broomfield, Melpomeni Kalofonou, Thomas Pataillot-Meakin, Sue M. Powell, Rayzel C. Fernandes, Nicolas Moser, Charlotte L. Bevan, Pantelis Georgiou

    Prostate cancer (PCa) is the second most common cause of male cancer-related death worldwide. The gold standard of treatment for advanced PCa is androgen deprivation therapy (ADT). However, eventual failure of ADT is common and leads to lethal metastatic castration-resistant PCa. As such, the detection of relevant biomarkers in the blood for drug resistance in metastatic castration-resistant PCa patients could lead to personalized treatment options. mRNA detection is often limited by the low specificity of qPCR assays which are restricted to specialized laboratories. Here, we present a novel reverse-transcription loop-mediated isothermal amplification assay and have demonstrated its capability for sensitive detection of AR-V7 and YAP1 RNA (3 × 101 RNA copies per reaction). This work presents a foundation for the detection of circulating mRNA in PCa on a non-invasive lab-on-chip device for use at the point-of-care. This technique was implemented onto a lab-on-chip platform integrating an array of chemical sensors (ion-sensitive field-effect transistors) for real-time detection of RNA. Detection of RNA presence was achieved through the translation of chemical signals into electrical readouts. Validation of this technique was conducted with rapid detection (<15 min) of extracted RNA from prostate cancer cell lines 22Rv1s and DU145s.


  • Top Cited Papers
    Open Access

    Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum

    by Shenglin Cai, Thomas Pataillot-Meakin, Akifumi Shibakawa, Ren Ren, Charlotte L. Bevan, Sylvain Ladame, Aleksandar P. Ivanov, Joshua B. Edel

    MicroRNAs (miRNAs) play essential roles in post-transcriptional gene expression and are also found freely circulating in bodily fluids such as blood. Dysregulated miRNA signatures have been associated with many diseases including cancer, and miRNA profiling from liquid biopsies offers a promising strategy for cancer diagnosis, prognosis and monitoring. Here, we develop size-encoded molecular probes that can be used for simultaneous electro-optical nanopore sensing of miRNAs, allowing for ultrasensitive, sequence-specific and multiplexed detection directly in unprocessed human serum, in sample volumes as small as 0.1 μl. We show that this approach allows for femtomolar sensitivity and single-base mismatch selectivity. We demonstrate the ability to simultaneously monitor miRNAs (miR-141-3p and miR-375-3p) from prostate cancer patients with active disease and in remission. This technology can pave the way for next generation of minimally invasive diagnostic and companion diagnostic tests for cancer.


  • 3-Methylcytosine in Cancer: An Underappreciated Methyl Lesion?

    by Thomas Pataillot-Meakin, Nischalan Pillay, Stephan Beck